insulin
-
Consumer / Employer, Health Tech
Amazon’s Automatic Coupons for Diabetes Products While “Incremental” Will Still Be a “Gamechanger,” Experts Say
Amazon Pharmacy announced Tuesday that it is launching automatic coupons for more than 15 insulin and diabetes care brands. The move, while incremental, solves a major pain point for consumers with diabetes, as many struggle to afford insulin products.
-
Eli Lilly’s Insulin: Cheaper for Patients Without Much Financial Hit to the Firm
Eli Lilly is slashing prices for its insulin products and capping a patient’s monthly out-of-pocket costs at $35. But a financial analyst notes that the company can afford to cut prices on older medicines like insulin because the strategy will help it maintain pricing power for innovative new drugs.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
California lawsuit targets insulin costs as Biden also takes aim in SOTU
High prices have drawn other critics, as well, including President Joe Biden. He renewed his call for a broad price cap during his annual State of the Union address. Pharma companies insist they have been part of the solution.
-
Claiming Insulin Price Conspiracy, CA Sues Lilly, Novo Nordisk, Sanofi & PBMs
California’s Office of the Attorney General contends that drugmakers and pharmacy benefit managers work together to “aggressively raise the list price of insulin in lockstep with each other to artificial levels.” Insulin manufacturers deny the allegations, pointing to availability of lower-cost versions of their products.
-
Nonprofit drugmaker Civica Rx unveils plans for insulin biosimilars, $30 per vial
Civica Rx plans to make lower cost versions of three branded insulin products, biosimilars that are expected to reach the market in 2024. In addition to $30 vials, Civica plans to sell pen cartridges at $55 for a box of five.
-
Medicare drug price negotiation provision could avoid concerns about stifling innovation
Not all drugs will be subject to price negotiation under the revised legislation. But the agreement sets up a framework enabling Medicare to negotiate the prices of medicines that have been on the market for a long time, and also caps the monthly price of insulin, which has been a flashpoint of drug price debate.
-
Walmart rolls out discounted insulin, but patients still grapple with high prices
Walmart struck a deal with Novo Nordisk to offer a heavily discounted, private-label version of its fast-acting analog insulin. But it still doesn’t solve the pricing problems patients have faced, with insulin costs skyrocketing in recent years.
-
Insurers will limit insulin costs to $35 copay for Medicare Part D plans next year
More than 1,750 Medicare part D plans and Medicare Advantage plans will limit out-of-pocket insulin costs to a $35 copay next year. The change would make patients’ out-of-pocket costs more consistent than the current system, where payments fluctuate in different stages of their Part D plan.
-
Senators threaten to subpoena Cigna in insulin cost probe
Senators Chuck Grassley and Ron Wyden are demanding that Cigna turn over documents on insulin pricing, as part of a larger probe on rising insulin costs. The lawmakers claim that large pharmacy benefit manager Express Scripts, which Cigna acquired in 2018, is failing to comply with the investigation.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Amid high insulin prices, many patients turn to unregulated sales on Craigslist, study shows
While many sellers were found to express altruistic motives, the researchers wrote that improperly stored insulin creates risks of lost potency and contamination. The findings highlight the need for substantive policy reform, according to the study’s lead author.
-
FDA hopes to spur insulin biosimilar development with easier clinical trial requirements
In a draft guidance, the agency proposed guidelines reducing the need for clinical trials to test insulin biosimilars for the potential to provoke immune system reactions. European regulators stopped recommending immunogenicity trials for insulin biosimilars in 2015.
-
Can changing rebate rules stop the ‘carousel’ of insulin pricing hikes?
At an event during the annual American Diabetes Association Scientific Sessions in San Francisco, representatives from PBM, health plan, drug manufacturing and patient advocacy groups came together to discuss the causes of increasing insulin prices and potential solutions to the problem.
-
MedCity Influencers, BioPharma
Diabetes, Deming’s perfect system and the value of home self-monitoring
Edwards Deming’s rule that “Every system is perfectly designed to get the results it gets” is perfectly on display in the wrongheaded way patients who are dependent on insulin get their medication at higher costs. The system can be redesigned by employers and others.
-
Cigna, Express Scripts to cap out-of-pocket costs for insulin at $25 under new program
A company representative said that while a full list of covered products isn’t available, the plan is to include all forms under the program, which could help more than 700,000 people in a Cigna or Express Scripts plan.
-
Digital health leader Derek Newell joins Virta Health as Head of Commercial
Prior to founding health benefits platform Jiff (which was acquired by Castlight in 2017), Newell worked for years in the remote care monitoring and chronic disease management space.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
